| |
Companion diagnostics play a vital role in oncology therapeutic development, but evolving regulations are changing the game. Join our webinar for expert guidance on adapting your assay development and study design strategies. Register to stay ahead!
|
|
Today’s Big NewsJan 24, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now.
|
|
| By Gabrielle Masson After what many considered a “slow” year for initial public offerings, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. |
|
|
|
By Nick Paul Taylor Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading. |
By Gabrielle Masson AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. |
By James Waldron The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic biotech Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins the Nasdaq with a $126.4 million offering. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By Darren Incorvaia,Zoey Becker Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after landing on Fabrice Chouraqui. Chouraqui was most recently a CEO-partner at Flagship Pioneering and previously served as president of Novartis Pharmaceuticals USA. |
By Andrea Park,Darren Incorvaia,Angus Liu,Zoey Becker This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
By Kevin Dunleavy Department of Health and Human Services secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing Merck over the marketing and sale of one of its vaccines. RFK Jr.’s plans raise conflict-of-interest questions as he is seeking confirmation to run an agency that regulates vaccines. |
By Darren Incorvaia Flagship Pioneering is leveraging its year-old London outpost to forge new research collaborations across the pond. The biotech incubator is teaming up with the U.K.’s Cambridge University Health Partners and the Milner Therapeutics Institute to advance breakthrough science and technologies, the firm announced Jan. 23. |
By Angus Liu Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. |
By Angus Liu Takeda's R&D chief explained the company's new investment priorities. AstraZeneca and Daiichi Sankyo's second antibody-drug conjugate has won its initial FDA approval in breast cancer. Fosun Pharma's attempt to privatize Henlius Biotech has failed. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
